SAB Biotherapeutics Files 8-K with Financials and Warrant Details
Ticker: SABSW · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, warrants, disclosure
TL;DR
SAB Biotherapeutics filed an 8-K on 9/9/24 detailing financials and warrants, formerly Big Cypress Acquisition Corp.
AI Summary
SAB Biotherapeutics, Inc. filed an 8-K on September 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company was formerly known as Big Cypress Acquisition Corp. and changed its name on November 20, 2020. The filing includes information about warrants exercisable for common stock at $11.50 per share.
Why It Matters
This filing provides updated financial information and details regarding outstanding warrants, which are crucial for investors to assess the company's financial health and potential dilution.
Risk Assessment
Risk Level: medium — The filing involves financial statements and details about warrants, which can impact share price and dilution, requiring careful investor analysis.
Key Numbers
- $11.50 — Warrant Exercise Price (Price at which warrants can be exercised for common stock.)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former company name
- September 09, 2024 (date) — Date of report
- November 20, 2020 (date) — Date of name change
- $11.50 (dollar_amount) — Warrant exercise price
FAQ
What is the primary purpose of this 8-K filing for SAB Biotherapeutics, Inc.?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of September 9, 2024.
When did SAB Biotherapeutics, Inc. change its name from Big Cypress Acquisition Corp.?
The company changed its name from Big Cypress Acquisition Corp. on November 20, 2020.
What is the exercise price for the warrants mentioned in the filing?
The warrants are exercisable for common stock at an exercise price of $11.50 per share.
What is the Commission File Number for SAB Biotherapeutics, Inc.?
The Commission File Number for SAB Biotherapeutics, Inc. is 001-39871.
What is the IRS Employer Identification Number for SAB Biotherapeutics, Inc.?
The IRS Employer Identification Number for SAB Biotherapeutics, Inc. is 85-3899721.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-09 08:21:33
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
Filing Documents
- sabs-20240909.htm (8-K) — 42KB
- sabs-ex99_1.htm (EX-99.1) — 21KB
- sabs-ex99_2.htm (EX-99.2) — 11KB
- sabs-ex99_2s1.jpg (GRAPHIC) — 251KB
- sabs-ex99_2s2.jpg (GRAPHIC) — 401KB
- sabs-ex99_2s3.jpg (GRAPHIC) — 570KB
- sabs-ex99_2s4.jpg (GRAPHIC) — 472KB
- sabs-ex99_2s5.jpg (GRAPHIC) — 487KB
- sabs-ex99_2s6.jpg (GRAPHIC) — 368KB
- sabs-ex99_2s7.jpg (GRAPHIC) — 279KB
- sabs-ex99_2s8.jpg (GRAPHIC) — 596KB
- sabs-ex99_2s9.jpg (GRAPHIC) — 363KB
- sabs-ex99_2s10.jpg (GRAPHIC) — 530KB
- sabs-ex99_2s11.jpg (GRAPHIC) — 443KB
- sabs-ex99_2s12.jpg (GRAPHIC) — 424KB
- sabs-ex99_2s13.jpg (GRAPHIC) — 351KB
- sabs-ex99_2s14.jpg (GRAPHIC) — 380KB
- 0000950170-24-104564.txt ( ) — 8375KB
- sabs-20240909.xsd (EX-101.SCH) — 46KB
- sabs-20240909_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 9, 2024, SAB Biotherapeutics, Inc., a Delaware corporation (the "Company" or "SAB"), issued a press release (the "Release") announcing that the Company's Chief Medical Officer will provide an update (the "Presentation") at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting, on the Company's Phase 1 clinical trial, investigating safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of SAB-142. A copy of the Release is filed herewith as Exhibit 99.1, and a copy of the Presentation is filed herewith as Exhibit 99.2. The information set forth in this Item 7.01, and in Exhibit 99.1 and Exhibit 99.2, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01, and in Exhibit 99.1 and and Exhibit 99.2, shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of the Company, dated September 9, 2024 99.2 Presentation of the Company, dated September 9, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: September 9, 2024 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer